Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...
NEWS CENTER Maine's Maria Skillings sat down with endo specialist Dr. Romeo Lucas to discuss the inflammatory disease that impacts one in 10 women worldwide.
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...
Health and Me on MSN
Sudden fractures could signal potential cancer, experts say
A bone fracture that happens after a minor fall or almost no injury at all might seem surprising, but doctors warn that in some cases it could be a hidden sign of cancer as certain cancers can weaken ...
The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...
During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.
Bezuclastinib is an oral, selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation, a primary driver of systemic mastocytosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results